Cough medication Corex by Pfizer has emerged the top selling brand in India with annual sales of Rs 182 crore during the year 2009, according to Stockist Secondary Audit data from drug sales tracking agency, ORG-IMS India.
The government of India has brought into effect stricter norms for obtaining No Objection Certificates (NOCs) for pharmaceutical exporters.
Cough medication Corex by Pfizer has emerged the top selling brand in India with annual sales of Rs 182 crore during the year 2009, according to Stockist Secondary Audit data from drug sales tracking agency, ORG-IMS India.
Dynavax Technologies Corporation has started clinical studies to compare the efficacy of its hepatitis B vaccine Heplisav with GSK's Engerix-B to see if fewer doses of the vaccine will be sufficient in adult patients.
A new pain killer code-named ADX71943 by Addex Pharmaceuticals has been shown the potential to treat several conditions including oteo-arthritis pains.
Palomid 529 (P529), an experimental therapy to treat age-related macular degeneration, has been entered into the first-in-man studies, Paloma Pharmaceuticals, Inc. announced.
Cough medication Corex by Pfizer has emerged the top selling brand in India with annual sales of Rs 182 crore during the year 2009, according to Stockist Secondary Audit data from drug sales tracking agency, ORG-IMS India.
Indian generic firm Lupin has received final approval for its amlodipine/benazepril capsules in US.
A new technology to reprogramme human cells into various cells developed by Fate Therapeutics has been granted patent in US.
Prostvac-VF, a therapeutic vaccine to treat prostate cancer by Bavarian Nordic, has been found prolonging the survival of patients with metastatic cancer.
Balaglitazone (DRF 2593), an investigative drug to treat diabetes cuts down HbA1c levels significantly, according to Dr. Reddy's and Rheoscience, the developers of the drug.
The government of India has brought into effect stricter norms for obtaining No Objection Certificates (NOCs) for pharmaceutical exporters.
World's top drug maker Pfizer will compensate the victims of unethical clinical trial in the African state of Kano using its menigitis vaccine Trovan with not less than N26, 250, 000 (Naira, nigerian currency) per person, reports said.
You can subscribe by email to receive newsletter updates:
Subscribe through a RSS feed reader
PILLSCRIBE ON TWITTER